ArticleJCO oncology advances2025

Phase II Study of Pexidartinib Plus Sirolimus in Unresectable Malignant Peripheral Nerve Sheath Tumors Identifies M2 Macrophage Activation.

Gulam A Manji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.